Heilman, R L <br/><br/>
Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab.  [electronic resource] 

 -  Transplantation proceedings  Jun 2006 
 - 1307-13 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0041-1345 
<br/><br/><label>Standard No.: </label>10.1016/j.transproceed.2006.02.116  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Disease<br/>Adrenal Cortex Hormones<br/>Adult<br/>Aged<br/>Animals<br/>Antibodies, Monoclonal--adverse effects<br/>Antilymphocyte Serum--adverse effects<br/>Basiliximab<br/>Female<br/>Graft Rejection--epidemiology<br/>Humans<br/>Immunosuppressive Agents--adverse effects<br/>Kidney Transplantation--immunology<br/>Male<br/>Middle Aged<br/>Patient Selection<br/>Rabbits<br/>Recombinant Fusion Proteins--adverse effects<br/>Risk Factors